RxDoctor Payments Data

Brandi Meads

Family · Oxford, ALNPI 1447623038

Payments from drug & device makers

$11,168in general payments, 2019–2025

Across 727 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Novo Nordisk$936
  • Atland Pharmaceuticals, LLC$706
  • Lilly USA, LLC$655
  • Indivior Inc.$525
  • plus $4K from 36 others

What the payments were for

  • Speaking & faculty fees$5004%
  • Food & beverage$10,66896%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,168 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$256
Medicare patients
22
Services billed
35

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide101$117,111
OzempicSemaglutide54$77,716
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl218$44,341
VraylarCariprazine Hcl16$25,259
RexultiBrexpiprazole13$18,944
JardianceEmpagliflozin16$16,435
TrulicityDulaglutide13$14,643
Liothyronine Sodium196$13,964
SuboxoneBuprenorphine Hcl/Naloxone Hcl13$9,580
Emgality SyringeGalcanezumab-Gnlm12$8,143
Emgality PenGalcanezumab-Gnlm12$7,040
ProgesteroneProgesterone, Micronized81$3,838
LantusInsulin Glargine,hum.Rec.Anlog12$2,967
Ondansetron OdtOndansetron144$2,033
Vilazodone Hcl13$1,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$655$131,754114 claims
Novo NordiskOzempic$936$77,71654 claims
AbbVieVraylar$2,127$25,25916 claims
Otsuka America Pharmaceutical, Inc.Rexulti$468$18,94413 claims
Boehringer IngelheimJardiance$18$16,43516 claims
Indivior Inc.Suboxone$525$9,58013 claims
Acella Pharmaceuticals, LLCNp Thyroid$72$1,03620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.

Other family in Oxford

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →